Publications by authors named "Angelo Semeraro"

Claim this Profile
T
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib.
Giuseppe Lopalco, Eleonora Celletti, Maria Morrone, Fabiola Atzeni, Massimiliano Limonta, Angelo Semeraro

Rheumatology (Oxford)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients.
Fabiola Atzeni, Cinzia Rotondo, Cesare Siragusano, Addolorata Corrado, Alberto Cauli, Angelo Semeraro

J Clin Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.
Giuseppe Lopalco, Maria Morrone, Fabiola Atzeni, Chiara Bazzani, Francesco Paolo Bianchi, Angelo Semeraro

Ther Adv Musculoskelet Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry.
Maria Sole Chimenti, Mauro Fatica, Marco Fornaro, Giuseppe Lopalco, Addolorata Corrado, Angelo Semeraro

Clin Exp Rheumatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Fabiola Atzeni, Angelo Semeraro

Arthritis Res Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry.
Marco Fornaro, Stefano Stano, Delia Goletti, Angelo Semeraro, Francesco Paolo Cantatore

Eur J Clin Invest· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of low-dose thiazide treatment in hypertensive patients associated with improvement in glycemic profile.
Alberto Preda, Angelo Semeraro, Giorgio Fiore, Luca Liberale, Fabrizio Montecucco

Intern Emerg Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
Roberta Ramonda, Mariagrazia Lorenzin, Antonio Carriero, Maria Sole Chimenti, Raffaele Scarpa, Angelo Semeraro

RMD Open· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
Ennio Giulio Favalli, Fabrizio Conti, Carlo Selmi, Florenzo Iannone, Romano Bucci, Angelo Semeraro

Clin Exp Rheumatol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Ennio G Favalli, Andrea Becciolini, Antonio Carletto, Fabrizio Conti, Giorgio Amato, Angelo Semeraro

Rheumatol Int· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
Florenzo Iannone, Angelo Semeraro, Giorgio Carlino, Leonardo Santo, Romano Bucci

Clin Drug Investig· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
Florenzo Iannone, Leonardo Santo, Romano Bucci, Angelo Semeraro, Giorgio Carlino

Clin Rheumatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
Florenzo Iannone, Leonardo Santo, Romano Bucci, Angelo Semeraro, Giorgio Carlino

Clin Rheumatol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Florenzo Iannone, Leonardo Santo, Maria Grazia Anelli, Romano Bucci, Angelo Semeraro

Semin Arthritis Rheum· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review.
Ennio Lubrano, Antonio Spadaro, Giorgio Amato, Maurizio Benucci, Ilaria Cavazzana, Angelo Semeraro

Semin Arthritis Rheum· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Luca Quartuccio, Martina Fabris, Elena Pontarini, Sara Salvin, Alen Zabotti, Angelo Semeraro

Ann Rheum Dis· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
Martina Fabris, Luca Quartuccio, Ed Vital, Elena Pontarini, Sara Salvin, Angelo Semeraro

Arthritis Rheum· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should low-dose methotrexate therapy be prescribed to dialysis patients?
Carlo Basile, Alessio Montanaro, Angelo Semeraro

Nephrol Dial Transplant· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis